Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (GB:0HX7)
LSE:0HX7
Adicet Bio (0HX7) Share Price & Analysis
0 Followers
0HX7 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.10 - $7.31
Previous Close$2.12
Volume43.00
Average Volume (3M)4.79K
Market Cap
$172.56M
Enterprise Value$33.77M
Total Cash (Recent Filing)$159.71M
Total Debt (Recent Filing)$20.92M
Price to Earnings (P/E)N/A
Beta0.81
Next Earnings
May 08, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding82,153,984
10 Day Avg. Volume18
30 Day Avg. Volume4,792
Standard Deviation0.26
R-Squared0.05
Alpha-0.00678
Financial Highlights & Ratios
Price to Book (P/B)0.97
Price to Sales (P/S)1709.65
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue47.30
Enterprise Value/Gross Profit47.30
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$9.20Price Target Upside374.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Adicet Bio News
PremiumCompany Announcements
Adicet Bio Showcases Promising ADI-270 Cancer Therapy Data
PremiumPre-Earnings
Is ACET a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe FDA has approved Adicet's IND for lupus nephritis, allowing the company to proceed with clinical trials.
Financial StabilityAdicet's strong cash position, with approximately $271 million in cash and equivalents, provides a solid financial foundation and a cash runway into the second half of 2026.
Regulatory MilestoneAdicet has received FDA Fast Track Designation for ADI-001 in the treatment of B-cell non-Hodgkin’s lymphoma, accelerating the development process.
Bears Say
EarningsAdicet reported 2023 EPS of $(3.31), indicating a loss per share for the year.
Product LaunchLaunch expectations for ADI-001 have been moved to 2027 from 2026, reflecting a more conservative timeline.
Stock ValuationAnalyst lowers price target to $10 from $26 due to the dilution from the most recent capital raise.
---
Options Prices
Currently, No data available
---
Ownership Overview
26.27% Insiders
4.28% Mutual Funds
6.64% Other Institutional Investors
62.81% Public Companies and
Individual Investors
0HX7 FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest share price was $1.10 and its highest was $7.31 in the past 12 months.
What is Adicet Bio’s market cap?
Currently, no data Available
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is May 08, 2024 which is in 13 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Mar 19, 2024. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.697 by $0.007.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -$0.44.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 82,169,600 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.697. Following the earnings report the stock price went up 4.91%.
Which hedge fund is a major shareholder of Adicet Bio?
Among the largest hedge funds holding Adicet Bio’s share is Wexford Capital LP. It holds Adicet Bio’s shares valued at 28K.
---
Adicet Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.20 (374.23% Upside)
$9.20 (374.23% Upside)
Blogger Sentiment
Bullish
GB:0HX7 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $15.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-66.01%
12-Months-Change
Fundamentals
Return on Equity
-61.69%
Trailing 12-Months
Asset Growth
-37.31%
Trailing 12-Months
Company Description
Adicet Bio
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
---
0HX7 Stock 12 Months Forecast
Average Price Target
$9.20
▲(374.23% Upside)
Technical Analysis
Best Analysts Covering 0HX7
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
+5.49%
reiterated a buy rating last month
Copying Justin Zelin's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +5.49% per trade.
---